Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(24):1806-1807; doi:10.1093/jnci/dji457
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vastag, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vastag, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

FDA Considers Tightening Regulations for Direct-to-Consumer Advertising

Brian Vastag

The first 10% of the full text of this article appears below.

In August, the Pharmaceutical Researchers and Manufacturers of America (PhRMA) sought to curb growing public criticism over its consumer advertising practices by releasing voluntary advertising guidelines. The document stated that drug advertising should serve the public health by "increasing awareness about diseases" and "educating patients about treatment options."

The voluntary PhRMA guidelines are viewed by some as an attempt to placate the U.S. Food and Drug Administration, which is considering tighter regulations on consumer drug advertising. In November, the agency held a 2-day hearing to solicit input from consumer advocates and the drug industry on how to proceed.

Current guidelines, put in place in 1997, allow drug companies to advertise directly to consumers if such ads balance supposed benefits with possible risks. Drug companies must submit advertisements for FDA review only at the time of airing; the FDA has no power to force . . . [Full Text of this Article]

Balancing Risks

Ad Delays


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Health Aff (Millwood)Home page
A. Kallen, S. Woloshin, J. Shu, E. Juhl, and L. Schwartz
Direct-To-Consumer Advertisements For HIV Antiretroviral Medications: A Progress Report
Health Aff., September 1, 2007; 26(5): 1392 - 1398.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
G. A. Abel, R. T. Penson, S. Joffe, L. Schapira, B. A. Chabner, and T. J. Lynch Jr.
Direct-to-Consumer Advertising in Oncology.
Oncologist, February 1, 2006; 11(2): 217 - 226.
[Abstract] [Full Text] [PDF]